What Only Orphans Cote does

Only Orphans Cote, LLC is a privately held regulatory affairs consulting firm founded in June 2021 by Dr. Timothy Cote, former Director of the FDA Office of Orphan Products Development (2007-2011). The firm provides end-to-end regulatory support to biotechnology and pharmaceutical companies developing drugs for rare diseases, with a flagship offering of FDA and EMA Orphan Drug Designation (ODD) application services reporting first-attempt approval rates of 95% and 98% respectively, against a stated industry average of 35%. Its service portfolio also covers FDA meeting preparation, Investigational New Drug (IND) applications, Fast Track and Breakthrough Therapy Designations, OOPD grant writing, Qualified Infectious Disease Product (QIDP) designations, and 505(b)(2) NDA pathways.

The firm's underlying technology is human expertise rather than a proprietary platform: its methodology derives from Dr. Cote's personal experience deciding 1,400+ ODD applications at the FDA and drafting approximately 900 ODD applications as a consultant, supplemented by a small regulatory affairs team with translational medicine backgrounds and a dedicated Chief of Staff. Operations are based in Cambridge, MA (625 Massachusetts Avenue) with a secondary Washington, DC office and a wholly-owned Dublin, Ireland subsidiary handling EMA submissions.

The business model is professional services, charging for tangible written deliverables such as ODD applications and FDA briefing materials, with an initial 30-minute consultation offered free. Go-to-market is sales-led and consultative, anchored on Dr. Cote's personal involvement in every client engagement, with two business development leads (Tina Wang and Eric Smith-Sokol) managing prospecting and Asian-market relationships, supported by content marketing through the Orphan Minute video series, the Orphan Drug Insights Journal blog, and presence at major biotech conferences. The firm has served 120+ clients since July 2021 and reports a global footprint across North America, Europe, Asia, and the Middle East.

Name

Only Orphans Cote

Legal name

Only Orphans Cote, LLC

Website

https://only-orphans-cote.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Only Orphans Cote is a regulatory affairs consultancy founded in 2021 by former FDA OOPD Director Dr. Timothy Cote, providing FDA and EMA Orphan Drug Designation applications, IND preparation, and expedited program support to biotech and pharmaceutical companies developing rare disease therapies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Affairs Consulting

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Orphan drug designation
• FDA regulatory consulting
• Rare disease regulatory
• EMA orphan designation
• Expedited program submissions

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

1. Regulatory Consulting Services: Professional services for orphan drug regulatory affairs including ODD application writing, FDA meeting preparation, regulatory strategy, and grant writing. The company charges for tangible written products (applications) that advance client assets. Initial 30-minute consultation is free.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Only Orphans Cote is a boutique regulatory affairs consulting firm that exclusively helps biotech and pharmaceutical companies secure Orphan Drug Designation from the FDA and EMA. The firm drafts and submits ODD applications, prepares sponsors for FDA meetings (Pre-IND, INTERACT, Type A/B/C/D), supports IND and expedited program submissions, and develops regulatory strategy for rare disease drug programs. Engagements are anchored by Dr. Timothy Cote, former FDA Office of Orphan Products Development Director, who personally oversees client deliverables.

Product overview

Only Orphans Cote is a regulatory consulting firm offering a comprehensive suite of services for orphan drug designation and rare disease drug development. The core offering centers on FDA and EMA Orphan Drug Designation applications (reported 95% and 98% first-attempt success rates respectively), supplemented by regulatory strategy consulting, FDA meeting preparation across all meeting types (INTERACT, Pre-IND, Type A/B/C/D), Investigational New Drug (IND) application support, and expedited program navigation (Fast Track and Breakthrough Therapy Designations). Additional services include OOPD Grants Program support, Qualified Infectious Disease Product (QIDP) Designation, and 505(b)(2) NDA pathways. The firm also provides educational content through its Orphan Minute video series and Orphan Drug Insights Journal blog. Dr. Timothy Cote, former Director of the FDA Office of Orphan Products Development, leads the firm with direct experience from over 1,400 FDA OOPD decisions and approximately 900 written applications as a consultant.

Differentiator

Problem solved

Functional benefit

Products and services

• FDA Orphan Drug Designation Application Services End-to-end consulting service for biotech and pharmaceutical sponsors pursuing US FDA Orphan Drug Designation, including strategic assessment, regulatory guidance, prevalence data preparation, medical rationale drafting, FDA submission support, and ODD maintenance. Reported 95% first-attempt approval rate.
• EMA Orphan Drug Designation Services Comprehensive support for biotech and pharmaceutical sponsors pursuing European Medicines Agency Orphan Drug Designation, including application writing, epidemiology and prevalence data preparation, significant benefit articulation, annual reporting, and post-designation compliance. Reported 98% first-attempt approval rate.
• FDA Meetings Preparation and Support Expert preparation and moderation services for FDA meetings of all types (INTERACT, Pre-IND, Type A, B, C, D), including drafting meeting requests, briefing packets, and coordinating FDA compliance interactions for orphan drug and rare disease programs.
• Fast Track and Breakthrough Therapy Designation Services Regulatory consulting service navigating FDA expedited programs including Fast Track Designation and Breakthrough Therapy Designation, including eligibility assessment, submission support, and FDA interactions for orphan and rare disease drug candidates.
• Investigational New Drug (IND) Applications Preparation and submission of Investigational New Drug (IND) applications required before first-in-human studies, including pre-IND meeting integration, application review, analysis, and FDA submission management.
• Regulatory Strategy Consulting Assessment and development of comprehensive regulatory strategies for orphan drug programs at any development stage, ensuring optimal use of regulatory incentives and expedited pathways.
• OOPD Grants Program Support Turnkey grant application writing for the FDA OOPD Clinical Trials Grants Program, Natural History Studies Grants Program, and FDA Rare Neurodegenerative Disease Grant Program, supporting applications up to four months before annual deadlines.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• NanoViricides, Inc.coreImplementation/ SI/ Consulting Partner · 1 December 2025Only Orphans Cote signed a Master Services Agreement with NanoViricides, Inc. to develop orphan drug strategy for NV-387, a broad-spectrum antiviral drug candidate targeting Mpox, Smallpox, and Measles. The engagement involves preparing and prosecuting orphan drug designation applications with the US FDA, leveraging Dr. Timothy Cote's expertise as former Director of FDA OOPD. The agreement covers ODD applications that would qualify NanoViricides for tax credits, user fee exemptions, and up to seven years of market exclusivity upon approval. Only Orphans Cote subsequently prepared ODD applications for NV-387 for both measles and Mpox treatments.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Arriello: European regulatory affairs consultancy delivering orphan drug designation, EMA/FDA submissions and lifecycle regulatory support to rare disease biotechs. Direct competitive overlap with Only Orphans Cote on EMA ODD work.
• Regulatory Pharma Net (RPN): Specialized regulatory affairs consultancy offering FDA and EMA regulatory strategy, orphan drug support and submission services to small and mid-sized biotechs. Closely comparable in scope, size and client base.
• BlueReg Group: European-headquartered regulatory affairs consultancy serving biotech clients on EMA orphan designation, clinical trial applications and marketing authorization. Direct peer for Only Orphans Cote's EMA pathway practice.
• Worldwide Clinical Trials: Mid-sized CRO with deep rare disease and orphan drug expertise across regulatory strategy, clinical operations and FDA interactions. Most direct comparable in mission and customer segment to Only Orphans Cote's specialty practice.
• ProPharma Group: Regulatory and compliance consulting firm offering FDA/EMA regulatory affairs, orphan drug strategy and submissions support to biotech and pharma. Closest peer in business model (boutique regulatory consultancy) to Only Orphans Cote.

Broad incumbents

• IQVIA: Global CRO that acquired Dr. Cote's prior consultancy (Coté Orphan) in 2017 and offers orphan drug regulatory services within its broader R&D Solutions portfolio. Direct competitive overlap on FDA/EMA ODD submissions but bundled with clinical and commercial scale.
• Parexel International: Large global CRO with a dedicated Regulatory & Access consulting practice covering FDA/EMA orphan designation, IND/NDA strategy and expedited program navigation. Competes for the same biotech sponsor budgets with broader clinical and commercialization offerings.
• ICON plc: Top-five CRO providing regulatory affairs and strategic consulting across rare disease programs, including FDA/EMA submissions and orphan designation work. Targets similar biotech and pharma clients with end-to-end development capabilities.
• Charles River Laboratories: CRO with regulatory and early-stage drug development services including rare disease support. Less specialized than Only Orphans Cote in orphan designation but competes for biotech regulatory consulting budgets.
• Syneos Health: Biopharmaceutical services organization with regulatory consulting capabilities that intersect with rare disease and expedited pathway work. Larger scale, broader portfolio and likely overlap with Only Orphans Cote's pharma client base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/only-orphans-cote-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Only Orphans Cote